Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
NCT05636436Phase 1Completed
- Sponsor
- MAXVAX Biotechnology
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant herpes zoster vaccine (CHO cells) in herpes zoster (HZ) (11 arms), sponsored by MAXVAX Biotechnology. Primary endpoints: Adverse Events at 30 days and Abnormal Laboratory Test Results at Day 4. Started Dec 2022; status: completed.
02
Drugs
recombinant herpes zoster vaccine (CHO cells)
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05636436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636436.